MXXIX
Price
$47.66
Change
-$0.17 (-0.36%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

MXXIX vs RPTIX

Header iconMXXIX vs RPTIX Comparison
Open Charts MXXIX vs RPTIXBanner chart's image
Marsico Midcap Growth Focus Fund
Price$47.66
Change-$0.17 (-0.36%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
MXXIX vs RPTIX Comparison Chart
Loading...
VS
MXXIX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MXXIX is a Buy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. MXXIX (316M). RPTIX pays higher dividends than MXXIX: RPTIX (0.18) vs MXXIX (0.00). MXXIX was incepted earlier than RPTIX: MXXIX (25 years) vs RPTIX (9 years). MXXIX is a more actively managed with annual turnover of: 76.00 vs. RPTIX (21.70). MXXIX has a lower initial minimum investment than RPTIX: MXXIX (2500) vs RPTIX (500000). MXXIX annual gain was more profitable for investors over the last year : 41.63 vs. RPTIX (14.81). MXXIX return over 5 years is better than : 39.60 vs. RPTIX (15.09).
MXXIXRPTIXMXXIX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence25 years9 years-
Gain YTD25.2899.127277%
Front LoadN/AN/A-
Min. Initial Investment25005000001%
Min. Initial Investment IRAN/AN/A-
Net Assets316M31.4B1%
Annual Yield % from dividends0.000.18-
Returns for 1 year41.6314.81281%
Returns for 3 years-11.86-13.5787%
Returns for 5 years39.6015.09262%
Returns for 10 years127.49N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp